Regeneron, a prominent biotechnology company based in the United States, has announced plans to acquire 23andMe, a company known for its consumer genetic testing services. In its statement, Regeneron emphasized that it will comply with 23andMe’s existing privacy policy as well as all applicable laws governing data protection and privacy. The company assured customers that there will be no changes to 23andMe’s privacy policy or to the consumer genome services currently offered. The acquisition is not yet finalized and is subject to approval by the relevant court authorities. 23andMe, headquartered in San Francisco, is recognized for providing direct-to-consumer genetic testing kits and has a significant database of genetic information. The acquisition, once approved, could have implications for the biotechnology and genomics sectors, particularly regarding data privacy and the integration of consumer genetic data with pharmaceutical research. The announcement was made via GlobeNewswire on May 19, 2025.